Polymorphisms of cancer stem cell marker gene CD133 are associated with susceptibility and prognosis of gastric cancer.

Zhi-Fang Jia, Yan-Hua Wu, Dong-Hui Cao, Xue-Yuan Cao, Jing Jiang, Bao-Sen Zhou

Future Oncology 2017 May

AIM: This study was aimed to investigate the associations between single nucleotide polymorphisms of cancer stem cell marker genes, CD44 and CD133, and susceptibility and prognosis of gastric cancer.

PATIENTS & METHODS: Five single nucleotide polymorphisms in CD44 and CD133 genes were genotyped in 898 gastric cancer cases and 992 controls.

RESULTS: The A/C or C/C genotypes of CD133 rs2240688 were associated with decreased risk of gastric cancer comparing with the A/A genotype (odds ratio: 0.81; 95% CI: 0.67-0.97; p = 0.023). The T allele of CD133 rs3130 predicted a worse survival for gastric cancer patients receiving tumorectomy (hazard ratio: 1.28; 95% CI: 1.04-1.58; p = 0.020), independent from tumor node metastasis stage, vessel invasion and postoperational chemotherapy.

CONCLUSION: CD133 polymorphisms are promising biomarkers for genetic susceptibility and prognosis prediction of gastric cancer.

Full text links

We have located links that may give you full text access.

Show additional links to paperHide additional links to paper

PubMed

Add to Saved Papers

Get 1-tap access

Related Resources

For the best experience, use the Read mobile app

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app